Andreessen Horowitz's biotech investment signals a strategic shift, highlighting evolving VC priorities and potential sectoral realignments.
The post Braveheart Bio seeks $319M in IPO backed by a16z, signaling VC firm’s expanding appetite beyond crypto appeared first on Crypto Briefing.